IRVINE, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- Central Admixture Pharmacy Services, Inc. (CAPS®), an industry leader in adopting release testing, will present its quality assurance program at the American Society of Health-System Pharmacists (ASHP) Summer Meetings and Exhibition.
Representatives from CAPS will be at booth #426 from June 4-6 at the Minneapolis Convention Center to provide information about CAPS’ Test, Hold and Release (THRSM) program, providing 100 percent batch level release testing from our 503B facilities.
THR is designed to ensure that every sterile compounded drug batch from CAPS 503B outsourcing facilities meets the standards for cGMP release testing for sterility, potency, and endotoxin testing prior to release and shipment. CAPS also offers a Certificate of Release for each batch.
CAPS, a B. Braun company, was among the first outsourcing admixture pharmacies in the nation to adopt release testing.
"Our existing high quality standards are strengthened with THR, which requires 100 percent batch level release testing on all of our products," said Mike Koch, Senior Vice President, CAPS Professional Services. "When it comes to patient safety and the reputation of our customers for 503B products, we believe that THR for every batch is the only way to assure the level of quality that's demanded by pharmacists and clinicians to help enhance patient outcomes."
CAPS also will provide information about its release of Tromethamine solution, which is now available and supplied as a single dose 0.3 M 50 mL solution in a 60 mL syringe.
Like all of CAPS’ sterile compounded drugs, Tromethamine undergoes CAPS’ THR program.
About CAPS®
CAPS is the nation’s largest network of outsourcing admixture pharmacies. A pioneer in the outsourcing of CSPs, CAPS was founded in 1991, and delivers high-quality, same-day, admixture services and solutions to hospitals and outpatient facilities across the nation. CAPS has two 503B Outsourcing Facilities that are registered with the FDA to provide anticipatory compounding services. CAPS also has 22 state licensed 503A regional pharmacies that dispense labeled, patient-specific prescriptions including parenteral nutrition. To learn more, visit www.capspharmacy.com.
About B. Braun
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the health care industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®.
Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.